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ABSTRACT 
 
Malaria afflicts about 500 million people worldwide thus causing significant global 
economic toll.  The drugs available to treat the disease are rapidly losing their efficacy because 
of widespread prevalence of drug resistant parasites. Thus there is an urgent need to discover 
novel malaria therapeutics. This research is focused on to study the properties of a novel natural-
like synthetic scaffold and analyze its selectivity, and cellular mechanism of action in 
Plasmodium falciparum. We have identified a novel compound, 3-amino-2-piperidinequinoline 
(APQ), which we termed UCF401. APQ demonstrated IC50 at submicromolar concentrations 
against Plasmodium falciparum using the SYBR Green-I fluorescence assay measuring cellular 
proliferation. This compound also demonstrated low cytotoxicity against the NIH3T3 and 
HEPG2 cells using MTS assays, showing an IC50 of 174 μM and 125 µM respectively, 
suggesting of excellent selectivity. We evaluated the compliance of APQ with Lipinski’s parameters 
and determined the in vitro physicochemical profiles of the compound. Our results show that APQ is a 
Lipinski parameter compliant and has good physicochemical properties. The cellular mechanism of 
action of APQ was characterized through the assessment of the effects of the compound at 
different stages of the parasite’s intraerythrocytic life cycle. This assay was done by treating a 
synchronized cell line with the compound at 5X the IC50 value and then imaging the cells at 12-
hour intervals. We found that APQ arrests parasite development at the trophozoite stage. In 
addition we determined that APQ is parasitocidal after a 96 h exposure. These results 
demonstrate that APQ can be considered as a validated hit and/or early lead. 
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CHAPTER ONE: INTRODUCTION 
Malaria Causing Agent 
 
Malaria is recorded by mankind throughout history, going back more than 4,000 years. It 
was often referred to as the “tertian” or “quartan” fever, due to its characteristic symptoms and 
patterns of expression [1]. The existence of these symptoms has been recorded by almost every 
major ancient civilization and its virulence and mortality have influenced many historical 
outcomes [1].  The term Malaria comes from the Italian words mal-aria, meaning “bad air” [1].  
It is not know who exactly coined the term but the disease’s causing agent was discovered by 
French surgeon Alphonse C. Laverans [1]. This pathogen is identified as a single cell eukaryotic 
microorganism belonging to the phylum Apicomplexa, (due to the presence of an organelle 
called the apicoplast), and the genus called Plasmodium, named by Ettore Marchiafava in the 
early 1900’s [2].  There are several Plasmodium species known to infect humans and cause 
disease, such as P. falciparum, P. vivax, P. ovale, P. knowlesi, and P. malariae; which are 
distributed worldwide, mostly in tropical and subtropical areas often having overlap within 
different species. Out of these species P. falciparum causes the most severe form of the disease 
and it is responsible for approximately a million deaths per year. P. vivax as well as P. ovale 
have dormant life stages (hypnozoites), they harbor in the hepatocytes and emerge when 
conditions allow. P. malariae uses a three-day life cycle (quartan cycle), while all the other 
species use a two-day life cycle (tertian cycle). This species can also cause a chronic, long lasting 
infection and disease.  Finally, P. knowlesi is known to be able to infect both humans and 
monkeys [1].  
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Plasmodium Life Cycle 
 
 The life cycle of the malaria pathogen is very complex and it involves the use of two 
hosts (Figure 1). The first host is the Anopheles female mosquito. When pregnant, the egg-
carrying mosquito must have a blood meal in order to sustain the nutritional requirements of the 
eggs. Once the Anopheles mosquito bites a malaria-infected individual, the mosquito uptakes the 
infected blood. Some of the parasites uptaken in this meal are in the gametocyte sexual life-
stage, and they will continue to develop as they travel, fusing with the lumen of the mosquito’s 
gut, transforming into a sporozoite-releasing oocyst. These sporozoites then travel to the salivary 
glands of the mosquito and stay there, waiting to be spread onto the next host when the mosquito 
feeds again and releases infected saliva into the host’s bloodstream [1]. This cycle is called the 
Sporogonic Cycle, and it usually takes from 10-18 days, depending on the conditions and species 
of Plasmodium [3].  The next cycle is called the Exo-erythrocytic cycle, which starts when the 
newly injected sporozoite travels through the bloodstream until reaching the liver, binding to and 
invading hepatocytes. Over the next 5-25 days these sporozoites reproduce exponentially through 
asexual binary fission, forming a compartmented structure called the liver schizont and reaching 
populations of up to 30,000 individual sporozoites, eventually rupturing the schizont and the 
hepatocyte, releasing merozoites. These merozoites escape the liver and travel through the blood 
stream seeking for the next target, the red blood cell (RBC), entering into the Human Blood 
Stage or the Erythrocytic life cycle. At this stage the merozoites invade the RBC and continue to 
mature, turning into immature trophozoites (ring stage), where then the cycle splits into some 
parasites entering the sexual erythrocytic cycle while others enter into the asexual erythrocytic 
cycle, maturing into trophozoites, followed by schizonts until finally rupturing the RBC and 
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escaping as merozoites, continuing the erythrocytic cycle. In the sexual erythrocytic cycle the 
immature trophozoites develop into male and female gametocytes, which are then uptaken by the 
Anopheles mosquito upon feeding, restarting the entire cycle again [4]. This complex life cycle 
makes it very difficult for researchers to find specific targets for the development of therapeutic 
treatments to combat this disease. 
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Figure 1: Plasmodium falciparum spp. life cycle [5] 
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Disease and Symptoms 
The Malaria disease clinical symptoms start developing once the exponentially 
reproduced merozoites escape from the hepatocytes into the bloodstream, binding, invading and 
rupturing the RBC, inhibiting it from performing its function, and expelling hemozoin into the 
bloodstream. Hemozoin is a toxic byproduct of the digestion of hemoglobin, which initiates a 
strong cytokine response [6], resulting in common symptoms such as fever, chills, sweats, 
headaches, nausea, vomiting, and general body aches. All of these symptoms are related to a 
typical inflammatory response. Infected RBCs also become more adhesive towards the 
endothelial tissues of the capillaries, obstructing proper blood flow to crucial organs. If 
untreated, malaria can complicate and cause severe symptoms related to organ failure and sepsis, 
such as cerebral malaria, coagulation abnormalities, hemoglobinuria, severe anemia due to 
hemolysis, acute respiratory distress syndrome (ARDS) caused by the decrease of oxygen 
delivery capacity, and enlarged liver and spleen [1]. 
Preventative Measures  
 
Since malaria is transmitted through a vector (Anopheles female mosquito), reducing the 
incidence of bites and the overall population of this mosquito species is the current approach for 
the prevention of malaria bouts. This is called vector control and is done by applying simple 
solutions that have a much greater impact; taking into consideration that the populations mostly 
affected by this disease are critically underdeveloped nations that lack the resources necessary to 
efficiently combat the problem at hand. Thus, the preventative measures must be simple to 
follow and affordable to maintain.  
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The most prevalent preventative measures being taken today are: 
• The use of Insecticide-treated bed nets and curtains (ITBC), which have proven to be highly 
effective at reducing the morbidity and mortality of malaria in African countries, since 
mosquitoes often feed at dusk and/or night [7], reducing the mosquito bites, reduces the cases 
and the spread of malaria. The setback with the implementation of this measure is 
affordability by the individual or community and non-compliance. To bypass these setbacks, 
communities depend on donors and the necessary education to increase the level of 
compliance. 
• The use of indoor residual spraying (IRS) involves the use of insecticides to reduce the 
population of the Anopheles mosquito. These insecticides vary from organochlorines, 
pyrethroids, organophosphates and carbamates. They are all highly effective, and their use 
depends mostly on susceptibility of the Anopheles species, environmental and human safety 
and cost-effectiveness. DDT, an organochlorine, is the most widely used insecticide, but its 
use is restricted for public health reasons, and to prevent the spread of resistance displayed by 
the Anopheles mosquito species [8]. The major setback to this measure is the affordability of 
the insecticide products, the environmental consequences, and the development of resistance 
to the chemical compounds by the Anopheles species. Again, the efficacy of this preventative 
measures depends on donors, global funding, and on education of the prudent use of 
insecticides to prevent resistance development [8].  
Current Treatments  
 
In addition to the preventive measures, a chemotherapeutic approach is also necessary in 
order to prevent disease, if used prophylactically, or to cure disease when a case occurs. These 
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measures alone do not prevent malaria emergence efficiently but do play a direct role in the 
decrease of mortality from an infection and the decrease of disease-spread. Thus, as mentioned 
above, it is critical to implement a combination of preventive and therapeutic measure to control 
the disease as efficiently as possible.  
There are many chemotherapeutic agents that have been found throughout history thanks to 
scientific research and drug development technologies. However, these compounds are also 
victims of affordability, sustainability, non-compliance, adverse health effects, and fast and 
widespread pathogenic resistance development. Hence, it is critical that the efforts and the search 
for effective antimalarial compounds must be continued globally to support drug development 
research and drug mass-distribution for the hardest-hit nations. In addition to patient and 
communal education, which should place focus on patient compliance. 
 
The most commonly used chemotherapeutic agents belong to several families of compounds, 
which are: 
• Endoperoxides 
• 4-aminoquinolines 
• 8-aminoquinolines 
• Antifolates 
• Sulfonamides 
• Antibiotics  
• Amino alcohols 
• Others 
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The major categories of chemotherapeutic agents and their mechanism of action will be 
discussed below (Figures 2 and 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Families of Chemotherapeutic Antimalarial Compounds [9]. 
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Figure 3: The different plasmodial life stages at which the most commonly used antimalarial compounds 
inhibit proliferation [9]. 
 
4- and 8- Aminoquinolines: 
 
The most important compound pertaining to this family of agents is chloroquine. 
Chloroquine has the ability to be used as both a prophylactic agent and a therapeutic agent as 
well. Chloroquine destroys the parasite by entering into the parasite digestive vacuole and 
binding hematin, which is a toxic (to the parasite) by-product of hemoglobin digestion by the 
parasite.  Normally, the hematin is polymerized into hemozoin crystals to reduce its toxicity to 
the parasite.  This detoxification is disrupted by chloroquine and the build-up of toxic hematin 
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destroys the parasite [10].  However the widespread use of chloroquine has rendered it almost 
useless throughout Africa due to the widespread development of drug resistance [1].  
Antifolates and Sulfonamides: 
 
Antifolates are chemical compounds that disrupt the folate biosynthesis pathway of 
Plasmodium species; this pathway is essential for DNA and RNA synthesis and the metabolism 
of certain amino acids. Amongst the antimalarial drugs currently in clinical use, the antifolates 
have the best-defined molecular targets, namely the enzymes dihydrofolate reductase (DHFR) 
and dihydropteroate synthase (DHPS) [11]. The most commonly used antifolate is 
Pyrimethamine. However, its use is limited by the ability of the parasite to uptake biosynthesized 
folates from the environment, where it is widely available as folic acid, defeating the purpose of 
an antifolate. Nevertheless, if used in combination with a sulfonamide such as sulfadoxine, the 
synergistic effect between the two compounds inhibits the parasite from uptaking exogenous 
folic acid [12]. This combination is widely used to substitute chloroquine usage, where resistance 
development has limited its effectiveness. 
Endoperoxidases: 
 
The most important and effective compound of this family, and in fact the most potent 
antimalarial compound used today is artemisinin. These compounds, derived from the leaves of 
the Artemisia annua plant, are extremely effective, providing a broad-stage inhibitory capacity 
and a very fast response compared to other antimalarial agents. Artemisinin is also effective 
against multi-drug resistant parasites. However, when artemisinin derivatives are administered as 
a monotherapy, the fast half-life and rapid excretion requires a prolonged treatment (minimum 
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duration, 7 days) to achieve a cure. On top of this, its fast-acting capacity and the need for 
prolonged administration, mixed with the inevitable patient non-compliance, makes this 
treatment vulnerable to developing resistance. For this reason, artemisinin is usually given in 
combination with a drug from the same family that has a longer half-life; this strategy is known 
as artemisinin-based combination therapy (ACT). The reason for ACTs success is that the short-
acting but highly effective artemisinin delivers a rapid reduction in parasitemia, with the 
remaining parasites being removed by the less effective but more slowly eliminated analogs. The 
ACTs have the additional benefit of dramatically reducing the production of gametocytes, the 
sexual stage of the parasite as a consequence of the rapid reduction in the parasite biomass. 
Displaying activity against both, the more mature asexual-stage parasites (the precursors of the 
sexual stages), as well as gametocytocidal activity against early gametocytes (stage I–III) [13].  
Antifolates and Sulfonamides, 4- and 8- Aminoquinolines and Endoperoxidases are the 
most widely used drug compounds against the war on malaria. The other chemical families of 
antimalarials and their compounds are often used in rare cases where resistance is emerging 
towards the mainstream drugs, or they can also be given in combination with these commonly 
used antimalarials. Shown below, in Table 1, is a summary of the most widely used antimalarial 
compounds, the region of most use, and the level of resistance acquired against it. This summary 
sheds light onto the global need for further scientific research with the goals of optimizing 
already present antimalarial compounds and creating and testing analogs of these already known 
compounds.  
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Table 1: Antimalarial compounds. Their chemical class, clinical use and level of resistance [14]. 
 
The best way to treat malaria is through a thorough and effective combination of 
preventative measures, to reduce the overall cases of infection, and an aggressive and compliant 
chemotherapy using the available drugs developed to treat and cure present occurrences.  
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Significance 
The malaria disease poses a great problem for humanity because it afflicts 40% of the 
global population, up to 3.3 billion people that live in areas in danger of malarial transmission. 
These areas comprise up to 106 countries, all of which are considered 3rd world countries from a 
socioeconomic perspective. This poses an even greater issue due to their lack of resources and 
their dependency on external aid from developed nations and organizations such as the World 
Health Organization (WHO). According to the WHO, an estimated 219 million cases of malaria 
with 660,000 deaths occurred in the year 2010, Up to 90% of deaths occur in the African region 
and 86% of these deaths occur in children under the age of 5. The great incidence of malaria 
throughout history makes it the highest selective pressure placed on humanity, killing more 
humans than any other disease. But there is hope for better statistics in the future, thanks to the 
conjunction of global awareness and efforts as well as scientific research and their developments; 
malaria mortality rates have decreased by more than 25% globally since 2000 [15]. If these 
global efforts continue to flourish into solutions for the issue at hand, then this trend is going to 
continue on to eradicate malaria from humanity. There are many obstacles to accomplish this, 
such as the ability of the parasite to develop drug resistance due to its complex genome, fast rate 
of reproduction, and its complex life cycle. These issues make it difficult for drug developers to 
find successful molecular targets. Nevertheless, malaria has been eradicated in developed nations 
by taking the necessary measures and one can argue that it will be accomplished globally if the 
continued global economic support and successful scientific findings for alternative and efficient 
treatments persists.  
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Purpose 
 
The drugs available to treat Malaria are rapidly losing their efficacy because of 
widespread prevalence of drug resistant parasites. Thus there is an urgent need to discover novel 
malaria therapeutics. This research is focused on the study of the properties of a novel natural-
like synthetic scaffold and the analysis of its selectivity, and cellular mechanism of action in 
Plasmodium falciparum. We aim to show its strength as a validated hit in order to promote it to 
early lead stage, in accordance to the parameters set by the Medicines for Malaria Venture 
(MMV). 
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CHAPTER TWO: THE POTENTIAL OF NATURE-LIKE PRODUCTS IN 
ANTIMALARIAL DRUG DISCOVERY  
Nature-like Products 
 
Historically, natural products (NPs) have been the central dogma of drug discovery [16]. 
From the use of plant extracts to treat disease to the discovery of antibiotics to treat infections 
(bacterial, fungal or parasitic), natural scaffolds have been the main resource for drug research 
and development [16]. The vast biodiversity of organisms that throughout millions of years of 
evolution have developed the necessary chemical arsenal to interact with their specific 
environment and ensure their survival and fitness is the main origin for the myriad of natural-
product derived drugs in current use and the incalculable amount of possibilities yet to be found 
[16]. Natural products are isolated from plants, algae, insects, bacteria, yeast, and animals. 
Approximately 25% of drugs in use today are derived from natural products, and in certain 
therapeutic areas, the impact is even higher, e.g., anti-cancer (74%) and anti-bacterial (78%) 
[17]. Thus, it is evident that these chemical templates produced by nature will yield higher 
quality and more accurate results in the drug research field, since these were originally 
synthesized to interact with biologically active molecules, and produced to outcompete other life 
forms [16].  
 Natural products have proven to be effective drugs. However, in the drug discovery and 
research field the majority of these products tend to be good lead compounds but often do not 
meet the demands for druggability. Druggability are the physicochemical, biochemical, 
pharmacokinetic and safety properties of drugs [18]. Modification or optimization of these 
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products, such as the elimination or substitution of functional groups or chirality centers, is often 
necessary in order to mitigate the undesired properties and activities of the lead NP compound 
while retaining the desired biological activity [18]. This leads to the synthesis of novel 
compounds that maintain a natural chemical template or scaffold and the enhancement of 
druggability and biological activity on desired targets as well as the decrease of 
chemotherapeutic instability and toxicity for the host, through the use of structure-activity 
relationship analysis and medicinal chemistry [18]. These novel compounds synthesized using 
natural scaffolds are known as synthetics derived natural products (SNPs) or nature-like 
products.  
Structure Activity Relationship 
 
The structure-activity relationship (SAR) analysis allows for the interchangeability of the 
chemical structure and configuration of a biologically active molecule in order to enhance its 
potency and effectiveness against its target and optimize its physicochemical properties and 
metabolic stability. This is done through the use of medicinal chemistry and the creation of 
chemical analogs of a lead compound in order to comply with the druggability parameters and 
standards of drug development and maintain the chemotherapeutic effect desired [19].  
Pharmacokinetic and Physicochemical Parameters  
 
 Since Malaria affects mostly areas of economic turmoil, an efficient drug ideally needs to 
be administered by the oral route, in order to eliminate the need of licensed professionals 
administering the drug and the use of resources that are already scarce in these areas e.g. 
syringes.  
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In General, a drug must comply with the following: 
• Must bind tightly to the biological target in vitro and in vivo 
• Must be permeable to one or more physiological barriers such as cell membranes 
• Bioavailability must be sustained for drug to take proper effect 
• Must be excreted from host by metabolism 
 
For a chemotherapeutic to have an effective physicochemical profile, it must comply with 
Lipinski’s rule of five (RO5) criteria [20]. Which are: 
• Molecular weight of < 500 g/mol  
• cLogP < 5 
• Less than 5 H-bond Donors (OH and NH groups) 
• Less than 10 H-bond Acceptors (N and O groups) 
• Polar surface area of less than 140 Angstroms squared [21]  
 
The chemotherapeutic also must have drug-like properties and a good ADME (absorption, 
distribution, metabolism, excretion) profile for oral bioavailability. These properties can be 
extrapolated from the elucidation of the following pharmacokinetic values: 
• Metabolic Stability: 
Measures the stability of the compound in the body and hence the excretion rate 
by metabolism. Poor metabolic stability means that compounds pass through liver 
metabolism readily after intestinal absorption via the portal vein, negatively 
affecting the bioavailability and increasing rapid elimination from the body. Liver 
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metabolism often alters the chemical structure of the compound, rendering it 
ineffective. Microsomal stability assays are done to measure the disappearance 
rate of the molecule in the presence of hepatic enzymes, such as cytochrome P450 
(CYP450) and Uridine 5'-diphospho-glucuronosyltransferase (UGT) [22], which 
are standard enzymes used in drug development research. This value is measured 
in percentage of drug available after 60 minutes [23].  
• Solubility: 
Solubility of the compound plays a central role in absorption through biological 
membranes. Poor solubility correlates with poor absorption. As a rule of thumb, a 
compound with an average potency of 1mg/kg should have a solubility of at least 
0.1g/L at pH 7.4 to be adequately soluble. If a compound with the same potency 
has a solubility of less than 0.01g/L it can be considered poorly soluble [24]. 
Solubility values are established through kinetic or thermodynamic solubility 
assays.  
• Distribution:  
After a drug enters the systemic circulation, it is distributed to the body's tissues. 
Distribution is generally uneven because of differences in blood perfusion, tissue 
binding (eg, because of lipid content), regional pH, and permeability of cell 
membranes [25]. Lipophilicity is a measure of several distribution factors and the 
molecules behavior in plasma [26]. It also shows relationship to plasma protein 
binding, permeation and solubility [26]. Lipophilicity values are found through 
partition coefficients clogP for neutral compounds, using a two-phase system of 
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octanol and water, and clogD for ionizable compounds using a pH range, usually 
logD at pH 7.4 [23]. A good partition coefficient value is less than 5.  
• Permeability 
As stated above, efficient antimalarials are ideally designed to be administered via 
oral route and absorbed through the intestinal lumen, the chemotherapeutics must 
be able to permeate through the several membranes to reach the systemic 
circulation. The most used approaches to study the permeation of the molecule 
across these barriers are enterocyte models such as Caco-2, or even an artificial 
membrane-assay called parallel artificial membrane permeability assay (PAMPA) 
[23][27].  
• Plasma-protein binding: 
The extent of binding to plasma influences the way in which a drug distributes 
into tissues in the body. If a compound is highly bound, then it is retained in the 
plasma, which results in a low volume of distribution. This may impact on the 
therapeutic effects of the compound by limiting the amount of free compound 
available to act on the target molecule. Extensive plasma protein binding also 
limits the amount of free compound available to be metabolized reducing the 
clearance of the compound [28]. Degree of binding is most usually elucidated 
using methods based on rapid equilbrium dialysis (RED). Results are usually 
expressed as percentage bound after 4 h using two varying concentrations, usually 
1 µM and 10 µM [29].   
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Medicines for Malaria Venture (MMV) and their compound progression criteria 
  
MMV, established in 1999 in Geneva, was the first public–private partnership of its kind 
to tackle a major global disease. This not-for-profit organization brings together public, private 
and philanthropic partners to fund and manage the discovery, development and delivery of 
affordable new medicines for the treatment and prevention of malaria in disease-endemic 
countries. They have established the standards and criteria to follow in the research and 
development of new chemotherapeutics against malaria in all of the pre-clinical stages of drug 
developments. The parameters for the two earliest stages of drug development (primary hits and 
validated hits) are as follows: 
1. Screening Hits 
a. IC50 at <1 μM in P. falciparum strains 3D7, HB3, Dd2, NF54, and W2   
2. Validated Hits 
a. Reproducibility of primary results (IC50 at <1 μM) 
b. If natural products are used, they must be acquired from a guaranteed source and 
their active species must be known. 
c. Activity against mammalian whole cells (minimum of two, being HepG2 one of 
them) shows >10-fold selectivity 
d. Has drug-like properties and does not violate Lipinski’s RO5.  
e. Computational ADME satisfactory 
f. Some basic SAR apparent 
g. Biological effects established: any stage specificity of action against blood stages 
(rings, trophozoites, or schizonts); cidal or static action determined.  
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Once compliant with these parameters, the researcher can move on to the next pre-
clinical drug development stages which are early leads and late leads, before the drug can be 
submitted as a development candidate [30].  
3-amino-2-piperidinequinoline 
 Preliminary research in our lab has focused in screening for antimalarial activity and 
selectivity of various natural product-like compounds commercially acquired from Asinex, a 
renowned chemical library provider. These compounds, derived from natural scaffolds, are 
enriched with features of known antimalarials, such as fused aromatic rings and protonable 
nitrogens, but excluding peroxide bridges, which are the leading characteristic of artemisinins. 
Within these compounds, primary hits with submicromolar antimalarial activity and broad 
selectivity were identified; 3-amino-2-piperidinequinoline (APQ), which we termed UCF401 is 
one of these primary hits.  
 APQ is characterized for having a quinoline scaffold with an amino group, which 
resembles widely used and proven antimalarials, this scaffold is also enriched with a piperidine 
group and a fluoride substituent. The chemical structure of APQ is advantageous for drug 
development since it does not posses any chiral centers, which translates into a single isomer 
structure without the need to worry for the stereoselectivity of the molecular target [31].  
 
 
 
 
 
 
  
Figure 4: 3-amino-2-piperidine-quinoline (APQ) chemical structure 
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 As a primary hit, APQ will be tested and analyzed in compliance with the MMV 
screening and validated hit parameters in order to promote the compound to early lead stage if 
the compound proves to be successful in all these criteria. We will be showing antimalarial 
potency, cytotoxicity assays in two human cell lines, cellular mechanism of action, and cidal vs. 
static activity for optimum dosage exposure time. The results of the antimalarial activity and 
selectivity will be validated through Z-scores and the assays will be independently repeated three 
times for reproducibility and further validation. In vitro Lipinski and ADME profiles for APQ 
were preliminarily acquired from the Sanford Burnham Pharmacology Core Facility at Lake 
Nona, Orlando. Finally, structure-activity relationship analysis will be performed on seven APQ 
analogs commercially acquired from the Asinex APQ library. These analogs will be tested for 
antimalarial efficacy and cytotoxicity in human cell lines. The results of this research are 
presented below.  
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CHAPTER THREE: METHODOLOGY 
Culturing P. falciparum 
P. falciparum Dd2 and 3D7 strains will be cultured using a modified Trager and Jensen 
method [32] in RPMI media with L-glutamine (Invitrogen) and supplemented with 25mM 
HEPES, 26 mM NaHCO3, 2% dextrose, 15mg/L hypoxanthine, 25mg/L gentamycin,  and 0.5% 
Albumax I.  Culture media will be changed daily and incubated at 37°C in 5% CO2 and 95% air. 
The 3D7 strain is a chloroquine sensitive strain characterized as chloroquine sensitive, 
pyrimethamine sensitive, mefloquine sensitive, and Artemisisin sensitive.  The Dd2 strain was 
used as a chloroquine resistant strain with resistance to chloroquine, pyrimethamine, and 
mefloquine but sensitivity to artemisinin. A blood smear will be taken daily and stained with 
Giemsa stain to determine parasitemia.  When parasitemia reaches above 10-15% the culture will 
be split down and resupplied with washed and 50% diluted A+ blood, which will be acquired 
from the Florida Blood Bank. 
Drug Sensitivity Assay and Malaria SYBR Green-I Fluorescence Assay (MSF)  
 
Given that the MSF assay is much cheaper and produces a quality equal to other well 
established but more complex and expensive methods for detecting P. falciparum inhibition, it 
will be chosen as the preferred method for the purpose of this research [33].  Because the P. 
falciparum host is the RBC, which has no DNA, and since SYBR Green is a known DNA 
intercalating agent, which will emit excitation-induced light only after binding to DNA. We can 
use this assay to quantify DNA levels and therefore, to quantify inhibition levels. Lower 
fluorescence values, means lower DNA concentrations and thus, lower parasitemia. 
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Different dilutions of the chemical compound in 1 µl of the culture medium will be added 
to 99 µl of P. falciparum culture at a 1% parasitemia and 2% hematocrit in 96-well plates. 
Maximum DMSO concentration in the culture will not exceed 0.125%. Chloroquine at 1 µM will 
be used as positive control to determine the baseline value of possible inhibition. Following 72 h 
incubation at 37ºC, the plates will be frozen at -80ºC. After thawing the plates at room 
temperature, 100 µl of lysis buffer (containing 20mM Tris-HCL, 0.08% Saponin, 5mM EDTA, 
0.8%Triton X-100, and 0.01% SYBR Green I) will be added to each well. Plates will be 
incubated in the dark for 30 minutes at 37ºC [33], followed by fluorescence emission reading 
which will be done using a Synergy H4 hybrid multimode plate reader (Biotek) set at 485 nm 
excitation and 530 nm emission.   
Sorbitol Synchronization of P. falciparum 
 
The pRBCs at a stage not later than ring stage and no later than 10-12 h post invasion will 
be treated with sorbitol by spinning down the culture at 600x gravity to a pellet, 4 ml of 5% 
sorbitol in dH2O will be added and the resulting mix will be incubated for 10 min at room 
temperature. This solution will be centrifuged again at 600x gravity and washed 3 times in 
malaria culture medium, diluting it to 4% hematocrit. This procedure will be repeated after one 
cycle (~48 h) and at least once a week to maintain synchronization [34]. 
Time Point Assays for Cellular Mechanism of Action Elucidation: 
In order to assess the effects of the chosen chemical compounds at each specific 
intraerythrocytic life stage of the parasite, a time point analysis will be performed. This will 
allow further understanding on the cellular mechanism of action of the specific compound. 
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Elucidating the specific intraerythrocytic stage at which the compound is most effective, while 
giving some insight as to which molecular target the compound is acting upon. This assay will be 
done by synchronizing parasitized RBCs (pRBCs) through the sorbitol synchronization protocol 
and then treating the synchronized cell line with the compound at 5x the IC50 value, previously 
obtained. Parasites will be cultured in the presence and absence of each compound at 5% 
parasitemia and 1% hematocrit, and incubated under the conditions described above. Treatments 
will be maintained for 36 h and the morphology of treated parasites will be compared to the 
control group every 12 h by examining Giemsa-stained thin blood smears. 
Assessment of the effect of parasitocidal versus static activities 
In 24-well plates, 1-mL cultures P. falciparum at 0.5% asynchronous parasitemia and 
1.0% hematocrit were treated with 1.5 and 15 µM of APQ, 3 and 30 times the IC50 for this 
compound, respectively. Cultures lacking drug were used as controls. Separate cultures were set 
up for 24, 48, 72, 96, and 168 h drug exposure, at which time infected RBCs were washed three 
times and resuspended in fresh RPMI without compound. To monitor for growth after cultures 
had potentially overgrown, replicate cultures at 72 h were diluted 1:10 into fresh RPMI with or 
without drug at 1% hematocrit for the 96 and 168 h time points. Media was replaced on alternate 
days, and fresh erythrocytes at 1% hematocrit were added on opposite days of media 
replacement. P. falciparum growth was followed by microscopy [35].  
Human and Rodent Cell Lines Cytotoxicity Assay  
 Compounds were evaluated for cytotoxicity using NIH/3T3 rodent fibroblast cells and 
HepG2 (human hepatocytes) cells. A 384 well plate was seeded with 2,500 cells/well (total 
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volume 50µL) and incubated for 24 hours.  Serial dilutions of the compound were added to the 
plate and plates were incubated for an additional 48 hours. 20 µL MTS  [(3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), CellTiter 96® Aqueous 
non-radioactive cell proliferation assay, Promega] reagent was added to each well and the plates 
were incubated for an additional 3 hours.  Cell viability was obtained by measuring the 
absorbance at 490nm using Synergy H4 hybrid multimode plate reader (Biotek) [36].  
Sensitivity and Accuracy Statistical Analysis Formula 
In order to validate, recognize, and quantify the sensitivity and accuracy of the assays performed 
the Z-factor analysis will be utilized.  This assay was originally developed, for high throughput 
screening (HTS) validation [37]. The equation is listed below as Equation 1-1. The Z-factor is a 
number, which should range from 0 to 1.  The closer the score is to the value of 1, the higher the 
confidence in the results and the higher the accuracy of the values.  A value below 0.5 is 
considered invalid and will require alterations or the assay to be redone.  A value between 0.5 
and 1 is considered acceptable and valid quality data. 
𝑍 − 𝑓𝑎𝑐𝑡𝑜𝑟 = 1 ± 3�(𝜎𝑝 − 𝜎𝑛)(𝜇𝑝 − 𝜇𝑛)� 
Equation 1: The Z-factor formula  
σp represents the standard deviation of the positive controls and σn is the standard 
deviation of negative controls.  Also, µp represents the mean of the positive controls and µn 
represents the mean of the negative controls [37].  
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CHAPTER FOUR: RESULTS 
Antimalarial Activity 
 
 The antimalarial activity of APQ was characterized through Malaria SYBR Green-I 
Fluorescence assay. This method measures the fluorescence concentration, which correlates to 
the amount of living parasites in culture. SYBR Green-I is a double-stranded DNA intercalating 
agent that emits light-induced fluorescence when bound to DNA. The reasoning behind this 
method is that the P. falciparum host, the RBC, does not have DNA of its own as it does not 
have a nucleus. Hence, the only DNA present in the parasitized RBC is uniquely plasmodial 
DNA. This allows us to correlate the percent parasitemia to the fluorescence reading. This 
experiment allows us to measure parasite proliferation after 72-hours of exposure to APQ at 
different concentrations, in order to generate a dose response curve and an IC50 value.  
 Following MMV parameters, a validated hit should have a submicromolar IC50, ideally   
≤ 500 nM. We determined that APQ has an IC50 of 500 nM, successfully complying with such 
parameter. We also generated a dose-response curve, which is displayed below (Figure 5).  
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Figure 5: APQ Half maximal inhibitory concentration (IC50) dose response curve against 
Plasmodium falciparum strain Dd2. The IC50 value was found at a concentration of 0.5 µM. 
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Cytotoxicity Against Human and Rodent Cell lines 
Dose Response Curve Against NIH3T3 Rodent Fibroblasts 
 We determined APQ’s cytotoxicity to NIH3T3 Rodent Fibroblasts by using the MTS 
assay. In this assay fibroblasts are incubated in the presence of different concentrations of APQ. 
MTS is added after the incubation period. MTS is a clear substance that is metabolized in the 
fibroblast mitochondria into a red-purple dye called formazan. The higher the metabolic rate and 
the shift in color of the substance correlates to the amount of living cells. This is a colorimetric 
assay read through absorbance. With the absorbance values, we determined the IC50 of our drug 
in fibroblasts cells to be 175 µM. Comparing this value to the submicromolar IC50 of APQ, we 
can confirm that APQ is up to 350 more potent in P. falciparum than in NIH3T3 fibroblasts. 
Giving us a selectivity index of 350-fold. The MMV criteria for the selectivity parameter in a 
validated hit is of at least > 10-fold. Our compound, APQ, clearly complies with this criterion. 
We also generated a dose-response curve, which is displayed below (Figure 6).  
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Figure 6: APQ Half maximal inhibitory concentration (IC50) dose response curve against NIH3T3 
Fibroblasts. The IC50 value was found at a concentration of 175 µM. 
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Dose Response Curve Against HepG2 Hepatocytes  
 
 The same assay done with NIH3T3 fibroblasts was performed in HepG2 human 
hepatocytes. Following the same analysis, we determined the IC50 of APQ in HepG2 cells to be 
at 125 µM, meaning 250-fold selectivity for P. falciparum and also clearly complying with 
MMV criteria for selectivity. We also provide a dose-response curve for this assay, which is 
found below (Figure 7).  
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Figure 7: APQ Half maximal inhibitory concentration (IC50) dose response curve against HepG2 
Hepatocytes. The IC50 value was found at a concentration of 125 µM. 
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Cellular Mechanism of Action 
 
Time Point Assays for Cellular Mechanism of Action Elucidation: 
 
 The time point assay was done to determine at which stage of the intraerythrocytic cycle 
is our drug carrying out its effects. We applied APQ to a synchronized culture at different stages 
of the blood cycle. These stages were ring (0 h), late ring/early trophozoite (12 h), trophozoite 
(24 h), schizont (36 h) and finally, reinfection which is represented by a new line of parasites at 
the ring stage (48 h). We took images at each of these time points in order to qualitatively 
analyze any changes in the growth pattern of the parasite when in the presence of APQ. We used 
DMSO as our negative control and Artemisinin as our positive control. DMSO is known to be 
harmless to the parasites and Artemisinin is in current use as an antimalarial compound. The 
figure below (Figure 8) shows our findings.  
 DMSO permits for proper growth, development, reproduction and reinfection of the 
parasite. Artemisinin arrests growth and development at the trophozoite stage. We determined 
that APQ also arrests growth and stage progression at the tropozoite stage, it does so however, at 
a later timepoint than Artemisinin, as its seen by the differences in size and morphology when 
comparing images of the APQ and Artemisinin effects in the same timepoints.   
 It is suggested by MMV criteria for compound progression that the cellular mechanism of 
action should be determined for validated hits in order to progress to lead stages of drug 
development.  
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Figure 8: Varying the life stage at which parasites are exposed to APQ demonstrates that APQ is efficient at 
arresting parasite development during the trophozoite stage.  Timepoint images were taken after exposing the 
pRBCs to APQ at 5X IC50 at 0, 12, 24, 36, and 48 hours post-infection respectively. DMSO and Artemisinin 
controls were included.  
 
 
 
 
 
 
 
 
 
 
 
  
APQ 
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Parasitocidal Vs. Parasitostatic Activity 
 
We determined that our compound, APQ, is parasitocidal after 96-hours of exposure. To 
determine this, we cultured our parasites in the presence of APQ at 3X and 30X the IC50 
concentrations. We exposed the parasites to APQ for 24 h, 48h, 72 h, 96 h, and 168 h in 
simultaneous cultures. We removed APQ from the media after the stated times by repeatedly 
washing our culture and plating them in fresh media and red blood cells. We then monitored 
parasite growth through microscopy for up to 300 hours after treatment removal. We found that 
APQ at a 30X IC50 is parasitocidal for all time-points and requires 96-h exposure to eliminate 
parasitemia completely. DMSO and Artemisinin controls were used.  
 MMV criteria for validated hits suggest that the parasitocidal vs. parasitostatic 
information is determined before the compound can be promoted to lead stages. We include 
graphs of our parasitemia behavior after the drug was removed for the 24 h, 48 h, 72 h and 96 h 
exposure to APQ below (Figure 9). 
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Figure 9a: Parasitocidal vs. Parasitostatic activity at 24 and 48 hours of exposure to APQ at 3X and 30X IC50 
concentration 
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Figure 9b: Parasitocidal vs. Parasitostatic activity at 72 and 96 hours of exposure to APQ at 3X and 30X IC50 
concentration. Varying the length of exposure of APQ demonstrates that 96 h exposure of 30X IC50 APQ kills 
P. falciparum. P. falciparum Dd2 strain in RBC cultures were exposed to 3X IC50 or 1.5 µM, 30X IC50 or 15 
µM of APQ for varying lengths of time before washing the parasites free of drug and reculturing to test if the 
parasites are viable. DMSO and Artemisinin controls were included. 
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Structure-Activity Relationship  
 The structure activity relationship analysis was done by catalogue. We purchased a set of 
APQ analogs from the same chemical library supplier as our hit-compound (Asinex). We then 
analyzed their antimalarial efficacy by determining their respective IC50 and then their selectivity 
in NIH3T3 rodent fibroblasts. By analyzing the shift in antimalarial efficacy for the different 
substituent groups in these analogs, we found that the amino group on position-3 of the quinoline 
scaffold can be substituted by either an amide or a ketone while maintaining a submicromolar 
IC50, we also determined that the presence of the fluorine on position-7 of the quinoline scaffold 
also maintains submicromolar IC50. On the piperidine scaffold, changing the trimethoxybenzene 
ring for a morpholine ring also maintains good antimalarial efficacy. The best analog, UCF406, 
has a combination of a 3-amide and a 7-fluoride on the quinoline scaffold with a 2,6-
dimethylmorpholine on the piperidine scaffold, showing an IC50 of 0.63 µM. The selectivity is > 
100-fold for all the analogs. This structure activity analysis, although limited, since it is not done 
through medicinal chemistry, gives us a brief idea of what works and what doesn’t, analyses with 
higher scrutiny will be done in the future. Below, we show a table with the name, structure, 
acitivity and selectivity of each structural analog of our hit-compound APQ (Table 2).  
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Compound Structure Dd2 IC50 (µM) 3T3 IC50 (µM) 
APQ 
 
0.453 >100 
UCF402 
 
0.876 >100 
UCF403 
 
0.731 >100 
UCF404 
 
1.167 >100 
UCF405 
 
1.245 >100 
 
 
40 
UCF406 
 
0.6332 >100 
UCF407 
 
0.9034 >100 
UCF408 
 
0.68725 >100 
Table 2: Structure-Activity Relationship for APQ and its seven structural analogs by demonstrating 
antimalarial efficacy in Dd2 strain and cytotoxicity in NIH3T3 Fibroblasts. 
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Lipinski Parameters and ADME profile for APQ 
 The Lipinski analysis was done through computer software (ChemDraw) and confirmed 
through chemical database PubChem. The ADME profile was acquired through fee-for-service at 
the Sanford Burnham Pharmacology Core Facility at Lake Nona, Orlando. Our compound is 
compliant with Lipinski parameters and has a reasonable ADME profile. We show the values 
obtained for these parameters in the table below (Table 3).  
Table 3: Lipinski Parameters and ADME profile for APQ. Values were acquired from the Sanford Burnham 
Pharmacology Core Facility at Lake Nona, Orlando. Solubility was calculated by kinetic assays, permeability 
was calculated by parallel artificial membrane permeability assay (PAMPA), Microsome stability was 
calculated by rate of compound disappearance using CYP450 enzymes in mouse liver microsomes and plasma 
protein binding was calculated through rapid equilibrium dialysis (RED). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound APQ Obtained 
Lipinski 
Parameters 
(In Silico) 
Distribution coefficient - clogP 2.251 
Molecular Weight 425.5 
Hydrogen Bond Donors 2 
Nitrogen and Oxygen Atoms 6 
Polar Surface Area (sq. Angstroms) 69.84 
ADME profile 
Solubility pH 7.4 (µg/ml) >126 
Permeability pH 7.4 (-logPe) < 2.7 
Microsome Stability (% remaining at 60 min) 61.34 
Plasma Protein Binding (% bound after 4 h 1 µM/10 µM) 90.58/79.42 
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MMV Compound Progression Parameters applied to APQ 
 
The following table (Table 4) summarizes all of our results and compares them with the 
validated hit compound progression criteria set forth by the MMV in the parameters pertinent to 
physicochemical properties, pharmacokinetic properties and biological activity. This table allows 
us to verify and conclude that our compound, APQ, is compliant with all the MMV criteria for 
validated hit compound progression and is eligible to be promoted as a lead stage compound.  
Table 4: Comparison chart between the MMV Validated Hits Progression Criteria for novel compounds [30] 
and the physicochemical, pharmacokinetic, and biological properties of APQ. Our compound proves to be a 
promising candidate for the lead stages of drug development, due to its compliance to the parameters 
established by the MMV. 
  
 
Parameters MMV Criteria APQ Results 
Lipinski Profile 
Distribution coefficient - clogP < 5 2.251 
Molecular Weight < 500 425.5 
Hydrogen Bond Donors < 5 2 
Nitrogen and Oxygen Atoms < 10 6 
Polar Surface Area (sq. Angstroms) < 140 69.84 
ADME Profile 
Solubility pH 7.4 (µg/ml) ≥ 10  >126 
Permeability pH 7.4 (-logPe) Must be known < 2.7 
Microsome Stability (% remaining at 60 
min) Must be known 61.34 
Plasma Protein Binding (% bound after 4 
h at 1 µM/10 µM) Must be known 90.58/79.42 
Biological Activity 
IC50 against P. falciparum  ≤ 500 nm 500 nm 
Selectivity against Human Cell lines 
(HepG2 must be one of them) > 10 fold  >100 fold 
Cellular Mechanism of Action Must be known Arrested development at Trophozoite Stage 
Cidal vs. Static Activity Must be determined 
100% parasitocidal after 
96 hour exposure to 30X 
IC50 
Structure-Activity Relationship Analysis Must be performed Performed 
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CHAPTER FIVE: DISCUSSION  
UCF401 or 3-amino-2-piperidine-quinoline (APQ) has excellent qualities and a huge 
potential to be developed as a future antimalarial drug. It is compliant with the parameters 
corresponding to its current development stage (validated hit) set forth by the MMV, the leading 
organization involved in antimalarial drug discovery and implementation.  
APQ has potent efficacy against chloroquine resistant Plasmodium falciparum strain Dd2 
with IC50 values in the submicromolar range. Its efficacy was also previously tested by our 
laboratory against chloroquine sensitive strain 3D7 showing very similar IC50 values, which 
suggests that its mechanism of action and molecular target differs from chloroquine. APQ was 
also tested for selectivity against the human cell lines HepG2 hepatocytes and NIH3T3 
fibroblasts showing more than 100-fold selectivity for its target. These values promote APQ 
from a screening hit to a validated hit.  
To continue the development progression of our compound, we elucidated the cellular 
mechanism of action of APQ through cellular timepoint studies. We determined that APQ 
interacts with essential biological targets necessary for trophozoite stage progression onto the 
schizont and following developmental stages, since the parasite’s intraerythrocytic life cycle is 
arrested at the trophozoite stage (Figure 8). The next experiment performed on our compound 
tested for the optimal time of exposure to APQ necessary to kill the entirety of the parasites in 
culture. This was done through cidal vs. static assays. We determined that exposure to APQ for 
the duration of 96 hours at a concentration of 30X IC50 was sufficient for a complete 
parasitocidal effect (Figure 9). To corroborate such result, the culture was monitored daily for up 
to seven days, parasitemia remained at 0% after the 96 hours of exposure as mentioned above.  
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Following the progression scheme for our compound we analyzed the structure-activity 
relationships (SAR) by acquiring seven analogs from the Asinex library of APQ compounds. 
These compounds are close variations of APQ, differing in substituents and functional groups 
while maintaining the original scaffold. We analyzed these analogs for IC50 values against 
chloroquine resistant P. falciparum strain Dd2 and NIH3T3 fibroblasts. All analogs obtained 
excellent selectivity for P. falciparum but their efficacy against the parasites varied. Although 
the APQ analogs in this set of compounds contain several variations and different combinations 
of substituents, making difficult to correlate the changes in efficacy to a single difference from 
APQ, a trend in these modifications can be observed. The substitution of the amino group in 
position 3 of the quinoline portion by an amide or a ketone also shows submicromolar IC50 
values. Also, the presence of the fluoride on position 7 of the same compound shows 
permanency of submicromolar efficacy. Changes like lengthening the alkyl chain on the 
piperidine, adding methyl groups or the presence of three anisol groups on the benzene ring 
attached to the piperidine portion contributes to the hydrophobicity of the molecule and this 
alters the specificity to the yet to be known molecular target. Finally, to comply with the MMV 
requirements for compound progression, our lab in conjunction with the Sanford Burnham 
Pharmacology Core Facility at Lake Nona, Orlando, elucidated the pharmacokinetic and 
physicochemical properties of APQ. Our findings indicate that APQ is in compliance with 
Lipinski’s rule of five and displays a reasonable ADME profile. These features strengthen the 
potential of APQ.  
After performing the pertinent research on APQ for the corresponding stage of drug 
development, we can argue that APQ has a formidable and well-established incentive to be 
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further researched and the potential to be promoted to lead and developmental stages of drug 
development. We believe so because thus far, APQ has successfully complied with all the MMV 
compound progression parameters established for validated hits, as can be seen in table 4.  
Conclusion 
 
Malaria is a problem that concerns up to 3.3 billion people that reside in at-risk areas; it 
infects up to 200 million people yearly and it killed approximately 600 thousand in 2012 alone, 
as reported by the WHO. These numbers do not take into account the suspected high number of 
cases that go unreported due to the socioeconomic situation in the geographical regions where 
malaria is highly prominent. Most of these deaths occur in children under five years of age.  
There are current treatments available to cure malaria and mitigate the symptoms caused 
by it, but the complexity of P. falciparum, together with overuse of such treatments and patient 
incompliance have resulted in the emergence of treatment resistant parasite strains, rendering 
chloroquine, the former leading form of treatment, almost useless in most areas. Artemisinin 
combined therapies (ACT) are also beginning to fail due to the same cause in areas such as 
Southeast Asia [38].   
The need for novel therapeutics is top priority to wage war against this disease and 
eradicate it from our human populations as it has been done in the developed world. The 
Medicines for Malaria Venture (MMV) has placed a significant effort in this priority, facilitating 
guidelines and development schemes for scientists in the antimalarial drug discovery field all 
over the world to come up with such novel therapeutics.  
APQ, a nature inspired synthetic product is a validated hit compound with a very strong 
potential to continue on in the development pipeline. It shows high efficacy and potency against 
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P. falciparum and a very broad selectivity for its target, displaying very low cytotoxicity levels. 
It acts on the trophozoite stage of the parasite’s intraerythrocytic life cycle arresting further 
development from this stage, and it is efficient at killing the entirety of the parasites in culture 
following a 96-hour exposure. It is also within the ideal ranges of Lipinski parameters and 
displays reasonable pharmacokinetic properties. APQ, as a validated hit, complies with all the 
criteria set forth by the MMV, rendering it as a strong candidate for promotion and progression 
onto the lead stages of drug development. The APQ chemical scaffold is inspired by natural 
antimalarials, however it contains a combination of innovative chemical features that had not 
been tested in the past. With this compound and continued research we plan to make a 
substantial contribution to the field of antimalarial drug discovery with the ultimate goal of 
eradicating malaria from humanity.  
Future Directions  
 Continued research on APQ must be performed in order to further characterize it and 
elucidate its properties as a developable drug.  This research must of course follow lead stages 
parameters and criteria set forth by the MMV. Some of these procedures entail in vivo studies 
related to compound activity and pharmacokinetic stability on mouse models, the determination 
of the rate of resistance development by the parasites, the elucidation of a molecular target and 
mechanism of action, the possibility of lead optimization using medicinal chemistry and the 
verification of chemoprophylactic properties by the drug. Finally, it would be also prudent to 
assess if the compound APQ benefits synergistically by testing changes in its effectiveness when 
used with combination treatments. These, among other corresponding investigations that must be 
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done enlighten the direction that should be taken in order to keep advancing this natural like-
synthetic compound.  
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